Holmberg C I, Kukkonen J P, Bischoff A, Näsman J, Courtney M J, Michel M C, Akerman K E
Turku Centre for Biotechnology, University of Turku, and Department of Biochemistry and Pharmacy, Abo Akademi University, Finland.
Eur J Pharmacol. 1998 Dec 11;363(1):65-74. doi: 10.1016/s0014-2999(98)00780-8.
The ability of cloned human alpha2B-adrenoceptors heterologously expressed in Sf9 cells and endogenous alpha2B-adrenoceptors in NG 108-15 neuroblastoma x glioma cells to couple to increase of intracellular Ca2+ was studied. Ca2+ increases in NG 108-15 cells were detectable but slight, whereas those in alpha2B-adrenoceptor-expressing Sf9 cells were greater. In the latter, the maximum Ca2+ increase correlated positively, and the EC50-value of noradrenaline negatively, with the receptor expression density. The order of potency of the agonists was D-medetomidine ([D]-4-[5]-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole) > noradrenaline approximately = clonidine > oxymetazoline, with clonidine and UK14,304 (5-bromo-N-[4,5-dihydro-1H-imidazole-2-yl]-6-quinoxalinamine) being weak partial agonists. In Sf9 cells Ca2+ increases consisted of concomitant mobilization from an intracellular store and influx of extracellular Ca2+. In these cells alpha2B-adrenoceptor stimulation also increased the inositol 1,4,5-trisphosphate mass. We conclude that alpha2B-adrenoceptors can couple to intracellular Ca2+ increases which may involve prior activation of phospholipase C.
研究了在Sf9细胞中异源表达的克隆人α2B - 肾上腺素能受体以及NG 108 - 15神经母细胞瘤×胶质瘤细胞中的内源性α2B - 肾上腺素能受体与细胞内Ca2 +增加偶联的能力。在NG 108 - 15细胞中可检测到Ca2 +增加,但幅度较小,而在表达α2B - 肾上腺素能受体的Sf9细胞中Ca2 +增加幅度更大。在后者中,最大Ca2 +增加与受体表达密度呈正相关,去甲肾上腺素的EC50值与受体表达密度呈负相关。激动剂的效力顺序为D - 美托咪定([D] - 4 - [5] - [1 - (2,3 - 二甲基苯基)乙基] - 1H - 咪唑)>去甲肾上腺素≈可乐定>羟甲唑啉,可乐定和UK14,304(5 - 溴 - N - [4,5 - 二氢 - 1H - 咪唑 - 2 - 基] - 6 - 喹喔啉胺)为弱部分激动剂。在Sf9细胞中,Ca2 +增加包括细胞内储存库的同步动员和细胞外Ca2 +的内流。在这些细胞中,α2B - 肾上腺素能受体刺激还增加了肌醇1,4,5 - 三磷酸的量。我们得出结论,α2B - 肾上腺素能受体可与细胞内Ca2 +增加偶联,这可能涉及磷脂酶C的预先激活。